Par Drugs And Chemicals Limited · NSE:PAR
Par Drugs And Chemicals — Q3 FY22 Earnings Presentation
16 slides from Par Drugs And Chemicals's earnings presentation, Feb 10, 2022
Slide 1: Cover letter to NSE: Investors Presentation
PAR/CS/NSE/2021-22/70 To, Date: 10/02/2022 The Manager Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai- 400 051 Maharashtra Symbol - PAR, ISIN: INE04LG01015 Subject: Investors Presentation Ref.: Regulation 30 read wi
Slide 2: 9M/Q3-FY22 Earnings Presentation
9M/Q3-FY22 Earnings Presentation
Slide 3: Company Overview
Company Overview
Slide 4: Company Overview
3 Company Overview Operational Revenues (INR Mn) • Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development 194 218 148 and manufacturing of APIs. 199 134 164 • The Company today manufactures more than 28 diffe
Slide 5: Key Strengths
4 Key Strengths Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 18 APIs and 10 Fine Chemicals which are marketed domestically and exported. Global Presence: The Company is operating both in domestic and ex
Slide 6: Financial & Operational Highlights
FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 7: 9M/Q3-FY22 Financial & Operational Highlights
6 9M/Q3-FY22 Financial & Operational Highlights Q3-FY22 Financial Highlights Operational Highlights • Revenue growth was impacted in the quarter as the increase Revenue EBITDA EBITDA Margin in finished goods realisations, on account of rising input costs INR 169 Mn INR 35 Mn 20.71% on Raw Materials,
Slide 8: 9M/Q3-FY22 Financial Overview
9M/Q3-FY22 Financial Overview
Slide 9: Quarterly Financial Performance
8 Quarterly Financial Performance Income Statement (INR Mn) Q3-FY22 Q3-FY21 Y-o-Y Q2-FY22 Q-o-Q Income from Operations 169 163 3.7% 196 (13.8)% Total Expenses 134 124 8.1% 156 (14.1)% EBITDA 35 39 (10.3)% 40 (12.5)% EBITDA Margin 20.71% 23.93% (322) bps 20.41% 30 bps Finance Cost 1 - NA 2 (50.0)% De
Slide 10: YTD Financial Performance
9 YTD Financial Performance Income Statement (INR Mn) 9M-FY22 9M-FY21 Y-o-Y Income from Operations 530 445 19.1% Total Expenses 413 328 25.9% EBITDA 117 117 NA EBITDA Margin 22.08% 26.29% (421) bps Finance Cost 4 4 0.0% Depreciation 24 21 14.3% Other Income 2 1 100.0% Profit before Extra Ordinary It
Slide 11: Historical Income statement
10 Historical Income statement Income Statement (INR Mn) FY19 FY20 FY21 9M-FY22 Income from Operations 463 558 607 530 Total Expenses 381 464 448 413 EBITDA 82 94 159 117 EBITDA Margin 17.71% 16.85% 26.19% 22.08% Finance Cost 20 8 6 4 Depreciation 30 27 28 24 Other Income 1 1 2 2 Profit before Extra
Slide 12: Balance Sheet
11 Balance Sheet EQUITIES & LIABILITIES (INR Mn) FY20 FY21 H1-FY22 ASSETS (INR Mn) FY20 FY21 H1-FY22 Shareholder Funds 406 523 569 Non Current Assets 359 352 352 (A) Equity Share Capital 61 62 123 (A) Fixed Assets (B) Reserves & Surplus 345 461 446 (i) Tangible Assets 344 299 344 (ii) Capital work-i
Slide 13: Financial Highlights
12 Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 26.19% 607 22.08% 19.11% 558 530 463 18.87% 17.71% 424 16.85% 12.83% 8.60% 5.40% 3.54% 80 82 94 159 117 25 48 116 68 15 FY18 FY19 FY20 FY21 9M-FY22 FY18 FY19 FY20 FY21 9M-FY22 FY1
Slide 14: Capital Market Highlights
13 Capital Market Highlights Price Data (31st December, 2021) INR Shareholding Pattern as on 31st December, 2021 Face Value 10.0 Market Price 201.25 Public 26% 52 Week High/Low 310.60/58.45 Market Cap (Mn) 2,476.3 Promoters 52 74% Equity Shares Outstanding (Mn)** 12.3 1 Year Avg Trading Volume (‘000
Slide 15: Disclaimer
14 Disclaimer Par Drugs and Chemicals Limited: The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection w
Slide 16: Thank You
Thank You
Par Drugs and Chemicals — Q3 FY22 Earnings Presentation on 6ix